LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

LLY

1,013.19

-0.14%↓

JNJ

201.41

-1.06%↓

ABBV

225.57

-1.64%↓

UNH

332.41

-0.46%↓

AZN

90.4

-0.14%↓

Home・Aandelen Lijst・Gossamer Bio Inc

Gossamer Bio Inc

Open

SectorGezondheidszorg

3.27 -3.82

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

3.2800000000000002

Max

3.42

Belangrijke statistieken
By Trading Economics
Inkomsten	-9.9M -48M
Verkoop	1.8M 13M
EPS	-0.21
Winstmarge	-362.728
Werknemers	144
EBITDA	-10M -45M

Aanbevelingen
By TipRanks
Aanbevelingen	Strong Buy
12 Maanden Prognose	+215.79% upside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	180M 727M
Vorige openingsprijs	7.09
Vorige sluitingsprijs	3.27

Nieuwssentiment

By Acuity

50%

178 / 374 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Weak Bullish Evidence

1.06 / 1.23 Steun & Weerstand

Gossamer Bio Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

4 dec 2025, 20:41 UTC

Winsten

Belangrijke Marktbewegers

America's Car-Mart Rises on Better-Than-Expected 2Q Revenue, $300 Million Term Loan

4 dec 2025, 18:14 UTC

Acquisities, Fusies, Overnames

Big Yellow Says It Will Terminate Takeover Talks With Blackstone

4 dec 2025, 17:43 UTC

Belangrijke Marktbewegers

Acquisities, Fusies, Overnames

Brera Holdings Signs Non-Binding Term Sheet to Acquire RockawayX

4 dec 2025, 17:01 UTC

Winsten

TD Bank Pushes Up Dividend After Underlying Earnings, Revenue Beat Expectations -- Update

4 dec 2025, 23:45 UTC

Marktinformatie

Nikkei May Decline Amid Caution Over U.S. Labor Market, Japan Earnings -- Market Talk

4 dec 2025, 23:45 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 dec 2025, 21:54 UTC

Marktinformatie

Global Equities Roundup: Market Talk

4 dec 2025, 21:54 UTC

Marktinformatie

Warehouse's Strategy to Lift Margins Easier Said Then Done -- Market Talk

4 dec 2025, 21:50 UTC

Marktinformatie

Financial Services Roundup: Market Talk

4 dec 2025, 21:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 dec 2025, 21:48 UTC

Marktinformatie

Scales Hits Mark With Earnings Guidance -- Market Talk

4 dec 2025, 21:37 UTC

Winsten

Aerospace Start-Up Beta Posts Its First Earnings Report. The Stock Rises. -- Barrons.com

4 dec 2025, 21:36 UTC

Winsten

These Stocks Moved the Most Today: Meta Platforms, Salesforce, Snowflake, UiPath, Micron, Dollar General, Kroger, and More -- Barrons.com

4 dec 2025, 20:15 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

4 dec 2025, 20:15 UTC

Marktinformatie

Think Tank Calls For Bank of Canada Rate Hold Next Week -- Market Talk

4 dec 2025, 20:04 UTC

Marktinformatie

Natural Gas Futures Extend Gains as U.S. Grows Cold -- Market Talk

4 dec 2025, 19:54 UTC

Marktinformatie

Oil Futures Bolstered by Lasting Ukraine War, U.S. Macro Outlook -- Market Talk

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

EQB CEO: PC Financial Deal Adds Scale to Compete With Larger Canadian Banks

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

EQB CEO: PC Financial Tie-Up Brings Scale to Reach More Customers

4 dec 2025, 19:44 UTC

Acquisities, Fusies, Overnames

Equitable Bank Deal for PC Financial Adds Heft to Compete With Canada's Big Banks -- Interview

4 dec 2025, 19:33 UTC

Marktinformatie

Gold Inches Higher as Traders Continue to Mull ADP Jobs Report -- Market Talk

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Raises Concerns About Netflix's Bid for Warner Bros. Discovery -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Wrote to Warner Bros. Discovery Again Wednesday -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Paramount Wrote Netflix Deal With Warner Bros. Would Likely 'Never Close,' Monday Letter Says -- WSJ

4 dec 2025, 19:01 UTC

Acquisities, Fusies, Overnames

Another Round of Bids for Warner Bros. Discovery Due Thursday, Sources Say -- WSJ

4 dec 2025, 18:58 UTC

Marktinformatie

U.S.-Venezuela Military Tension Expected to Lift Oil Prices -- Market Talk

4 dec 2025, 17:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

4 dec 2025, 17:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

4 dec 2025, 16:41 UTC

Marktinformatie

Gold Rises as Traders Await U.S. Inflation Data -- Market Talk

4 dec 2025, 16:33 UTC

Marktinformatie

Winsten

Salesforce Customers Are Gaining Confidence in Agentforce -- Market Talk

Peer Vergelijking

Prijswijziging

Gossamer Bio Inc Prognose

Koersdoel

By TipRanks

215.79% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 10.8 USD 215.79%

Hoogste 15 USD

Laagste 8 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor Gossamer Bio Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan Gossamer Bio Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

1.06 / 1.23Steun & Weerstand

Bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

All events are bullish.

Sentiment

By Acuity

178 / 374 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Gossamer Bio Inc

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.